Abstract:Although, by age 40, individuals with Down syndrome (DS) develop amyloid-β (Aβ) plaques and tau-containing neurofibrillary tangles (NFTs) linked to cognitive impairment in Alzheimer’s disease (AD), not all people with DS develop dementia. Whether Aβ plaques and NFTs are associated with individuals with DS with (DSD +) and without dementia (DSD −) is under-investigated. Here, we applied quantitative immunocytochemistry and fluorescent procedures to characterize NFT pathology using antibodies specific for tau phosphorylation (pS422, AT8), truncation (TauC3, MN423), and conformational (Alz50, MC1) epitopes, as well as Aβ and its precursor protein (APP) to frontal cortex (FC) and striatal tissue from DSD + to DSD − cases. Expression profiling of single pS422 labeled FC layer V and VI neurons was also determined using laser capture microdissection and custom-designed microarray analysis. Analysis revealed that cortical and striatal Aβ plaque burdens were similar in DSD + and DSD − cases. In both groups, most FC plaques were neuritic, while striatal plaques were diffuse. By contrast, FC AT8-positive NFTs and neuropil thread densities were significantly greater in DSD + compared to DSD −, while striatal NFT densities were similar between groups. FC pS422-positive and TauC3 NFT densities were significantly greater than Alz50-labeled NFTs in DSD + , but not DSD − cases. Putaminal, but not caudate pS422-positive NFT density, was significantly greater than TauC3-positive NFTs. In the FC, AT8 + pS422 + Alz50, TauC3 + pS422 + Alz50, pS422 + Alz50, and TauC3 + pS422 positive NFTs were more frequent in DSD + compared to DSD- cases. Single gene-array profiling of FC pS422 positive neurons revealed downregulation of 63 of a total of 864 transcripts related to Aβ/tau biology, glutamatergic, cholinergic, and monoaminergic metabolism, intracellular signaling, cell homeostasis, and cell death in DSD + compared DSD − cases. These observations suggest that abnormal tau aggregation plays a critical role in the development of dementia in DS.

Unraveling the complexity of neurodegeneration in brains of subjects with Down syndrome: insights from proteomics

Age-Related Neurodegeneration and Memory Loss in Down Syndrome

Proteomics Study of Peripheral Blood Mononuclear Cells in Down Syndrome Children

Neurobehavioral dysfunction in a mouse model of Down syndrome: upregulation of cystathionine β-synthase, H2S overproduction, altered protein persulfidation, synaptic dysfunction, endoplasmic reticulum stress, and autophagy

Exosomal biomarkers in Down syndrome and Alzheimer's disease

A Common Link Between Alzheimer's Disease and Down Syndrome

Oxidative stress as a candidate mechanism for accelerated neuroectodermal differentiation due to trisomy 21

Analysis of microisolated frontal cortex excitatory layer III and V pyramidal neurons reveals a neurodegenerative phenotype in individuals with Down syndrome

Altered Brain Cholesterol Machinery in a Down Syndrome Mouse Model: A Possible Common Feature with Alzheimer's Disease

Frontal Cortex and Striatal Cellular and Molecular Pathobiology in Individuals with Down Syndrome with and Without Dementia

Inter-Dependent Mechanisms Behind Cognitive Dysfunction, Vascular Biology and Alzheimer's Dementia in Down Syndrome: Multi-Faceted Roles of APP

Cognitive and molecular characterization of the Ts66Yah murine model of Down syndrome: deepening on hippocampal changes associated with genotype and aging

Common genetic signatures of Alzheimer's disease in Down Syndrome

Aging exacerbates oxidative stress and liver fibrosis in an animal model of Down Syndrome

Oxidative Stress and Down Syndrome. Do Antioxidants Play a Role in Therapy?

Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein

Shaping down syndrome brain cognitive and molecular changes due to aging using adult animals from the Ts66Yah murine model

A Novel Mechanism Underlying Pathogenesis of Down Syndrome

The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model

Neuronal oscillations in cognition: Down syndrome as a model of mouse to human translation

Nrf2 stabilization prevents critical oxidative damage in Down syndrome cells